Neurocrine Biosciences, Inc.
NBIX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $14 | $12 | $11 | $14 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $14 | $13 | $11 | $14 |
| Revenue | $1 | $1 | $1 | $1 |
| % Growth | 15.6% | 20.1% | -8.8% | – |
| Gross Profit | $1 | $1 | $1 | $1 |
| % Margin | 98.2% | 98.4% | 98.4% | 98.5% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 37.7% | 22.2% | 5.5% | 28.9% |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | 26.4% | 15.6% | 1.4% | 16.4% |
| EPS Diluted | 2.04 | 1.06 | 0.08 | 1 |
| % Growth | 92.5% | 1,225% | -92% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |